Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

UNLIMITED UNderstanding Lipid ImmunoMetabolIsm To trEat Disease

Coordinator
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Germany
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€4.5m
Total cost
—
Partners
27 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227259

What the project is doing

In the project's own words, from its summary on CORDIS.

The UNLIMITED project addresses the critical challenges of lipid immunometabolism, a rapidly emerging field with transformative potential for treating immune-mediated diseases such as cancer, autoimmunity and metabolic disorders. Lipid metabolism has been recently recognized as a regulator of immune cell function, yet the intricate interactions between lipid pathways and immune responses within tissue-specific microenvironments remain poorly understood.

This knowledge gap hampers the development of precision therapies tailored to the metabolic needs of immune cells in diverse tissue niches. To tackle these challenges, UNLIMITED will train 15 Doctoral Candidates in cutting-edge interdisciplinary research, equipping them with expertise spanning immunology, bioinformatics, metabolism, and drug development. A key feature of UNLIMITED training programme is the integration of leading-edge methodologies, such as multi-omics machine learning, single-cell technologies, CRISPR-Cas9, and spatial metabolomics, alongside groundbreaking techniques pioneered by consortium partners, including SCENITH, Met-Flow, click-chemistry, LIPSTIC, and advanced lipidomics.

UNLIMITED’s training program emphasizes a holistic, interdisciplinary approach, providing DCs with technical skills, unparalleled expertise, and transferable competencies to thrive in academic and industrial sectors. The project will unlock unprecedented insights into how lipid metabolic pathways regulate immune cell function and adapt to changes in the tissue microenvironment. This knowledge will enable the identification of novel therapeutic targets and pioneering precision therapies for immune-related diseases.

This bold initiative strengthens Europe’s leadership in health innovation, creating a new generation of highly skilled researchers ready to transform global healthcare and advance therapeutic frontiers.

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsmedizin Der Johannes Gutenberg-Universitaet MainzMainzGermanyCoordinator
Biocrates Life Sciences AGInnsbruckAustriaAssociatedpartner
Medizinische Universitaet WienWienAustriaParticipant
ActiTrexx GmbHMainzGermanyAssociatedpartner
Johannes Gutenberg-Universitat MainzMainzGermanyAssociatedpartner
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyAssociatedpartner
Sonja NossWiesbadenGermanyAssociatedpartner
Technische Universitaet BraunschweigBraunschweigGermanyParticipant
Tress Academic GbRPlaneggGermanyAssociatedpartner
Universitat Zu KolnKolnGermanyParticipant
Samplix ApsBirkerodDenmarkAssociatedpartner
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (f.s.p.)MadridSpainParticipant
Universidad Autonoma De MadridMadridSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite D'aix MarseilleMarseilleFranceAssociatedpartner
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Universita Degli Studi Di MilanoMilanoItalyParticipant
Universita Degli Studi Di PadovaPadovaItalyParticipant
Vilniaus UniversitetasVilniusLithuaniaAssociatedpartner
Vugene UabKaunasLithuaniaParticipant
Luxembourg Institute of HealthStrassenLuxembourgParticipant
Universite Du LuxembourgEsch-Sur-AlzetteLuxembourgAssociatedpartner
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting VuAmsterdamNetherlandsAssociatedpartner
Sitryx Therapeutics LtdOxfordUnited KingdomParticipant
The University Court of the University of AberdeenAberdeenUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI